Charles Explorer logo
🇨🇿

Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?

Publikace na 2. lékařská fakulta |
2023

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

We read with a great interest the paper focused on different minimal residual disease (MRD) approaches and its significance in Ph+ acute lymphoblastic leukemia (ALL) patients, authored by Short et al. from the MD Anderson Cancer Center. We would like to thank the authors for this important data, and offer a short comment from our pediatric experience.